Results 151 to 160 of about 35,915 (205)

Hepatic safety of pretomanid- and pyrazinamide-containing regimens in TB Alliance clinical trials. [PDF]

IJTLD Open
Nedelman J, Li M, Olugbosi M, Bruning-Barry R, Ambroso J, Cevik M, Gillespie S, Sloan DJ, Beumont M, Sun E.   +9 more
europepmc   +1 more source

Population pharmacokinetics of pyrazinamide and isoniazid in plasma and cerebrospinal fluid from South African adults with tuberculous meningitis. [PDF]

Antimicrob Agents Chemother
Calderin JM, Wasserman S, Resendiz-Galvan JE, Abdelgawad N, Davis A, Stek C, Wiesner L, Wilkinson RJ, Denti P.   +8 more
europepmc   +1 more source

Phenotypic drug resistance and genome sequencing based identified mutations linked to resistance in Mycobacterium tuberculosis isolated from extrapulmonary clinical specimens. [PDF]

Sci Rep
Mollalign H, Alemayehu DH, Melaku K, Ayele A, Chala D, Diriba G, Yenew B, Getahun M, Adnew B, Moga S, Collins JM, Ghodousi A, Beyene D, Bobosha K, Wassie L.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pyrazinamide

Reactions Weekly, 2010
  +5 more sources